As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.
12 Analysts have issued a Candel Therapeutics Inc forecast:
12 Analysts have issued a Candel Therapeutics Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -35 -35 |
1%
1%
|
|
| EBIT (Operating Income) EBIT | -36 -36 |
2%
2%
|
|
| Net Profit | -22 -22 |
56%
56%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
| Head office | United States |
| CEO | Paul-Peter Tak |
| Employees | 38 |
| Founded | 2002 |
| Website | www.candeltx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


